Analysts expect that Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX – Get Rating) will announce $108.15 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Eagle Pharmaceuticals’ earnings, with estimates ranging from $107.50 million to $108.80 million. Eagle Pharmaceuticals posted sales of $48.12 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 124.8%. The business is expected to announce its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Eagle Pharmaceuticals will report full-year sales of $398.80 million for the current financial year. For the next financial year, analysts anticipate that the company will post sales of $292.55 million, with estimates ranging from $265.20 million to $319.90 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Eagle Pharmaceuticals.
Eagle Pharmaceuticals (NASDAQ:EGRX – Get Rating) last announced its quarterly earnings data on Monday, May 9th. The specialty pharmaceutical company reported $4.04 earnings per share for the quarter, beating the consensus estimate of $3.19 by $0.85. Eagle Pharmaceuticals had a return on equity of 18.56% and a net margin of 14.56%. During the same period in the previous year, the business posted ($0.03) earnings per share.
A number of hedge funds have recently added to or reduced their stakes in EGRX. Allspring Global Investments Holdings LLC acquired a new position in Eagle Pharmaceuticals in the fourth quarter valued at $14,018,000. Balyasny Asset Management LLC acquired a new position in Eagle Pharmaceuticals in the third quarter valued at $9,220,000. Goldman Sachs Group Inc. lifted its holdings in Eagle Pharmaceuticals by 65.3% in the first quarter. Goldman Sachs Group Inc. now owns 178,306 shares of the specialty pharmaceutical company’s stock valued at $8,825,000 after buying an additional 70,438 shares during the period. Two Seas Capital LP acquired a new position in Eagle Pharmaceuticals in the fourth quarter valued at $2,296,000. Finally, Krensavage Asset Management LLC lifted its holdings in Eagle Pharmaceuticals by 52.2% in the third quarter. Krensavage Asset Management LLC now owns 107,773 shares of the specialty pharmaceutical company’s stock valued at $6,012,000 after buying an additional 36,969 shares during the period. Institutional investors and hedge funds own 88.71% of the company’s stock.
Shares of NASDAQ EGRX opened at $46.94 on Friday. The stock has a market capitalization of $596.09 million, a price-to-earnings ratio of 16.95 and a beta of 0.68. The business has a 50-day moving average of $47.30 and a 200-day moving average of $48.36. Eagle Pharmaceuticals has a fifty-two week low of $36.48 and a fifty-two week high of $58.25.
About Eagle Pharmaceuticals (Get Rating)
Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.
- Get a free copy of the StockNews.com research report on Eagle Pharmaceuticals (EGRX)
- Airbnb: Bold Competitive Threats & A New World of Travel
- Is RBC Bearings Rolling Into A Reversal?
- Should Dollar General or Dollar Tree Give Investors a Case of FOMO?
- Genesco Pops On Earnings But Don’t Expect A Rally
- The Insiders Are Selling Movado Group, But You Shouldn’t
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.